FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004584168> ?p ?o ?g. }

• W2004584168 endingPage "951" @default.
• W2004584168 startingPage "945" @default.
• W2004584168 abstract "Background: Treatment of multinodular goiters (MNGs) is highly controversial. Radioiodine (RAI) therapy is a nonsurgical alternative for the elderly who decline surgery. Recently, recombinant human thyrotropin (rhTSH) has been used to augment RAI uptake and distribution. In this study, we determined the outcome of 30 mCi RAI preceded by rhTSH (0.1 mg) in euthyroid (EU) and hyperthyroid (subclinical/clinical) patients with large MNGs. Methods: This was a prospective cohort study. Forty-two patients (age, 43–80 years) with MNGs were treated with 30 mCi RAI after stimulation with 0.1 mg of rhTSH. Patients were divided into three groups, according to thyroid function: EU (n = 18), subclinically hyperthyroid (SC-H, n = 18), and clinically hyperthyroid (C-H, n = 6). All patients underwent a 90-day low-iodine diet before treatment, and those with clinical hyperthyroidism received methimazole 10 mg daily for 30 days. Serum TSH, free thyroxine (FT4), total triiodothyronine (TT3), and thyroglobulin were measured at baseline and at 24, 48, 72, 168 hours, and 1, 3, 6, 9, 12, 18, 24, and 36 months after therapy. Thyroid volume was assessed by computed tomography at baseline and every 6 months. Results: Patients had high iodine urinary excretion (308 ± 108 μg I/L) at baseline. TSH levels at baseline were within the normal range (1.5 ± 0.7 μU/mL) in the EU group and suppressed (<0.3 μU/mL) in the SC-H and C-H groups. After rhTSH, serum TSH peaked at 24 hours reaching 12.4 ± 5.85 μU/mL. After RAI administration, patients in both hyperthyroid groups had a higher increase in FT4 and TT3 compared with those in the EU group (p < 0.001). Thyroglobulin levels increased equally in all three groups until day 7. Thyroid volume decreased significantly in all patients. Side effects were more common in the SC-H and C-H groups (31.4% and 60.4%, respectively) compared with EU patients (17.8%). Permanent hypothyroidism was more prevalent in the EU group (50%) compared with the SC-H (11%) and C-H (16.6%) groups. Conclusions: Patients with MNG may have subclinical and clinical nonautoimmune iodine-induced hyperthyroidism. Despite a low-iodine diet and therapy with methimazole, hyperthyroid patients have a significantly higher increase in FT4 and TT3 levels after RAI ablation. This can lead to important side effects related mostly to the cardiac system. We strongly advise that patients with SC-H and C-H be adequately treated with methimazole and low-iodine diet aiming to normalize their hyperthyroid condition before rhTSH-stimulated treatment with RAI." @default.
• W2004584168 created "2016-06-24" @default.
• W2004584168 creator A5009040035 @default.
• W2004584168 creator A5011149867 @default.
• W2004584168 creator A5014978761 @default.
• W2004584168 creator A5072558282 @default.
• W2004584168 creator A5073526759 @default.
• W2004584168 creator A5086626649 @default.
• W2004584168 date "2009-09-01" @default.
• W2004584168 modified "2023-09-27" @default.
• W2004584168 title "High Prevalence of Side Effects After Recombinant Human Thyrotropin–Stimulated Radioiodine Treatment with 30 mCi in Patients with Multinodular Goiter and Subclinical/Clinical Hyperthyroidism" @default.
• W2004584168 cites W1967914320 @default.
• W2004584168 cites W1971664482 @default.
• W2004584168 cites W1974279346 @default.
• W2004584168 cites W1997556550 @default.
• W2004584168 cites W2000784270 @default.
• W2004584168 cites W2033676871 @default.
• W2004584168 cites W2037925360 @default.
• W2004584168 cites W2043015190 @default.
• W2004584168 cites W2053669525 @default.
• W2004584168 cites W2058689626 @default.
• W2004584168 cites W2059821948 @default.
• W2004584168 cites W2061228018 @default.
• W2004584168 cites W2069696291 @default.
• W2004584168 cites W2071716948 @default.
• W2004584168 cites W2093832760 @default.
• W2004584168 cites W2100270641 @default.
• W2004584168 cites W2100992577 @default.
• W2004584168 cites W2102109637 @default.
• W2004584168 cites W2122432540 @default.
• W2004584168 cites W2149926491 @default.
• W2004584168 cites W2154432650 @default.
• W2004584168 cites W2170043543 @default.
• W2004584168 cites W2185414486 @default.
• W2004584168 cites W2398607212 @default.
• W2004584168 cites W4230405862 @default.
• W2004584168 cites W4235713489 @default.
• W2004584168 cites W4251782485 @default.
• W2004584168 doi "https://doi.org/10.1089/thy.2008.0394" @default.
• W2004584168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19678745" @default.
• W2004584168 hasPublicationYear "2009" @default.
• W2004584168 type Work @default.
• W2004584168 sameAs 2004584168 @default.
• W2004584168 citedByCount "18" @default.
• W2004584168 countsByYear W20045841682012 @default.
• W2004584168 countsByYear W20045841682013 @default.
• W2004584168 countsByYear W20045841682014 @default.
• W2004584168 countsByYear W20045841682015 @default.
• W2004584168 countsByYear W20045841682016 @default.
• W2004584168 countsByYear W20045841682019 @default.
• W2004584168 countsByYear W20045841682022 @default.
• W2004584168 crossrefType "journal-article" @default.
• W2004584168 hasAuthorship W2004584168A5009040035 @default.
• W2004584168 hasAuthorship W2004584168A5011149867 @default.
• W2004584168 hasAuthorship W2004584168A5014978761 @default.
• W2004584168 hasAuthorship W2004584168A5072558282 @default.
• W2004584168 hasAuthorship W2004584168A5073526759 @default.
• W2004584168 hasAuthorship W2004584168A5086626649 @default.
• W2004584168 hasConcept C10146269 @default.
• W2004584168 hasConcept C113280763 @default.
• W2004584168 hasConcept C126322002 @default.
• W2004584168 hasConcept C126894567 @default.
• W2004584168 hasConcept C134018914 @default.
• W2004584168 hasConcept C188816634 @default.
• W2004584168 hasConcept C191897082 @default.
• W2004584168 hasConcept C192562407 @default.
• W2004584168 hasConcept C2776254400 @default.
• W2004584168 hasConcept C2777195454 @default.
• W2004584168 hasConcept C2778288131 @default.
• W2004584168 hasConcept C2778835679 @default.
• W2004584168 hasConcept C2778840127 @default.
• W2004584168 hasConcept C2909991657 @default.
• W2004584168 hasConcept C526584372 @default.
• W2004584168 hasConcept C539932907 @default.
• W2004584168 hasConcept C71924100 @default.
• W2004584168 hasConcept C72563966 @default.
• W2004584168 hasConcept C90924648 @default.
• W2004584168 hasConceptScore W2004584168C10146269 @default.
• W2004584168 hasConceptScore W2004584168C113280763 @default.
• W2004584168 hasConceptScore W2004584168C126322002 @default.
• W2004584168 hasConceptScore W2004584168C126894567 @default.
• W2004584168 hasConceptScore W2004584168C134018914 @default.
• W2004584168 hasConceptScore W2004584168C188816634 @default.
• W2004584168 hasConceptScore W2004584168C191897082 @default.
• W2004584168 hasConceptScore W2004584168C192562407 @default.
• W2004584168 hasConceptScore W2004584168C2776254400 @default.
• W2004584168 hasConceptScore W2004584168C2777195454 @default.
• W2004584168 hasConceptScore W2004584168C2778288131 @default.
• W2004584168 hasConceptScore W2004584168C2778835679 @default.
• W2004584168 hasConceptScore W2004584168C2778840127 @default.
• W2004584168 hasConceptScore W2004584168C2909991657 @default.
• W2004584168 hasConceptScore W2004584168C526584372 @default.
• W2004584168 hasConceptScore W2004584168C539932907 @default.
• W2004584168 hasConceptScore W2004584168C71924100 @default.
• W2004584168 hasConceptScore W2004584168C72563966 @default.
• W2004584168 hasConceptScore W2004584168C90924648 @default.
• W2004584168 hasIssue "9" @default.
• W2004584168 hasLocation W20045841681 @default.

• next